Your browser doesn't support javascript.
loading
Comparison of Volumetric and 2D Measurements and Longitudinal Trajectories in the Response Assessment of BRAF V600E-Mutant Pediatric Gliomas in the Pacific Pediatric Neuro-Oncology Consortium Clinical Trial.
Ramakrishnan, Divya; Brüningk, Sarah C; von Reppert, Marc; Memon, Fatima; Maleki, Nazanin; Aneja, Sanjay; Kazerooni, Anahita Fathi; Nabavizadeh, Ali; Lin, MingDe; Bousabarah, Khaled; Molinaro, Annette; Nicolaides, Theodore; Prados, Michael; Mueller, Sabine; Aboian, Mariam S.
Afiliação
  • Ramakrishnan D; From the Department of Radiology and Biomedical Imaging (D.R., M.v.R., F.M., N.M., M.L., M.S.A.), Yale School of Medicine, New Haven, Connecticut divya.ramakrishnan@yale.edu.
  • Brüningk SC; Department of Biosystems Science and Engineering (S.C.B.), ETH Zürich, Basel, Switzerland.
  • von Reppert M; Swiss Institute for Bioinformatics (S.C.B.), Lausanne, Switzerland.
  • Memon F; From the Department of Radiology and Biomedical Imaging (D.R., M.v.R., F.M., N.M., M.L., M.S.A.), Yale School of Medicine, New Haven, Connecticut.
  • Maleki N; Department of Neuroradiology (M.v.R.), Leipzig University Hospital, Leipzig, Germany.
  • Aneja S; From the Department of Radiology and Biomedical Imaging (D.R., M.v.R., F.M., N.M., M.L., M.S.A.), Yale School of Medicine, New Haven, Connecticut.
  • Kazerooni AF; From the Department of Radiology and Biomedical Imaging (D.R., M.v.R., F.M., N.M., M.L., M.S.A.), Yale School of Medicine, New Haven, Connecticut.
  • Nabavizadeh A; Department of Therapeutic Radiology (S.A.), Yale School of Medicine, New Haven, CT, USA.
  • Lin M; Center for Outcomes Research and Evaluation (S.A.), Yale School of Medicine, New Haven, Connecticut.
  • Bousabarah K; Center for Biomedical Image Computing and Analytics (A.F.K.), University of Pennsylvania, Philadelphia, Pennsylvania.
  • Molinaro A; Center for Data-Driven Discovery in Biomedicine (A.N.), Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Nicolaides T; From the Department of Radiology and Biomedical Imaging (D.R., M.v.R., F.M., N.M., M.L., M.S.A.), Yale School of Medicine, New Haven, Connecticut.
  • Prados M; Visage Imaging (M.L.), San Diego, Calfornia.
  • Mueller S; Visage Imaging (K.B.), Berlin, Germany.
  • Aboian MS; Department of Neurological Surgery (A.M.), University of California San Francisco, San Francisco, Calfornia.
AJNR Am J Neuroradiol ; 45(4): 475-482, 2024 04 08.
Article em En | MEDLINE | ID: mdl-38453411
ABSTRACT
BACKGROUND AND

PURPOSE:

Response on imaging is widely used to evaluate treatment efficacy in clinical trials of pediatric gliomas. While conventional criteria rely on 2D measurements, volumetric analysis may provide a more comprehensive response assessment. There is sparse research on the role of volumetrics in pediatric gliomas. Our purpose was to compare 2D and volumetric analysis with the assessment of neuroradiologists using the Brain Tumor Reporting and Data System (BT-RADS) in BRAF V600E-mutant pediatric gliomas. MATERIALS AND

METHODS:

Manual volumetric segmentations of whole and solid tumors were compared with 2D measurements in 31 participants (292 follow-up studies) in the Pacific Pediatric Neuro-Oncology Consortium 002 trial (NCT01748149). Two neuroradiologists evaluated responses using BT-RADS. Receiver operating characteristic analysis compared classification performance of 2D and volumetrics for partial response. Agreement between volumetric and 2D mathematically modeled longitudinal trajectories for 25 participants was determined using the model-estimated time to best response.

RESULTS:

Of 31 participants, 20 had partial responses according to BT-RADS criteria. Receiver operating characteristic curves for the classification of partial responders at the time of first detection (median = 2 months) yielded an area under the curve of 0.84 (95% CI, 0.69-0.99) for 2D area, 0.91 (95% CI, 0.80-1.00) for whole-volume, and 0.92 (95% CI, 0.82-1.00) for solid volume change. There was no significant difference in the area under the curve between 2D and solid (P = .34) or whole volume (P = .39). There was no significant correlation in model-estimated time to best response (ρ = 0.39, P >.05) between 2D and whole-volume trajectories. Eight of the 25 participants had a difference of ≥90 days in transition from partial response to stable disease between their 2D and whole-volume modeled trajectories.

CONCLUSIONS:

Although there was no overall difference between volumetrics and 2D in classifying partial response assessment using BT-RADS, further prospective studies will be critical to elucidate how the observed differences in tumor 2D and volumetric trajectories affect clinical decision-making and outcomes in some individuals.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioma Limite: Child / Humans Idioma: En Revista: AJNR / AJNR Am J Neuroradiol / AJNR am. j. neuroradiology Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Encefálicas / Glioma Limite: Child / Humans Idioma: En Revista: AJNR / AJNR Am J Neuroradiol / AJNR am. j. neuroradiology Ano de publicação: 2024 Tipo de documento: Article